Colleen Tupper Sells 1,949 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 1,949 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now directly owns 177,195 shares in the company, valued at $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $29.99 on Wednesday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $42.29. The firm has a 50-day simple moving average of $30.83 and a 200-day simple moving average of $33.10. The company has a market capitalization of $944.27 million, a price-to-earnings ratio of 12.93 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. On average, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently modified their holdings of COLL. Nisa Investment Advisors LLC raised its position in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Collegium Pharmaceutical by 1.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after acquiring an additional 339 shares during the period. AlphaQuest LLC raised its holdings in Collegium Pharmaceutical by 3.0% during the fourth quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock worth $366,000 after purchasing an additional 374 shares in the last quarter. Foundry Partners LLC lifted its position in Collegium Pharmaceutical by 2.4% in the fourth quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock valued at $463,000 after purchasing an additional 381 shares during the period. Finally, Gallacher Capital Management LLC boosted its holdings in Collegium Pharmaceutical by 3.3% in the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock valued at $417,000 after purchasing an additional 470 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on COLL shares. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Piper Sandler reduced their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.